{"id":98728,"date":"2026-08-06T18:27:23","date_gmt":"2026-08-06T18:27:23","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/98728\/"},"modified":"2026-08-06T18:27:23","modified_gmt":"2026-08-06T18:27:23","slug":"gsk-hits-three-month-high-as-vaccines-help-earnings-top-forecasts-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/98728\/","title":{"rendered":"GSK hits three-month high as vaccines help earnings top forecasts"},"content":{"rendered":"

\"GSK<\/a> GSK hits three-month high as vaccines help earnings top forecasts Proactive uses images sourced from Shutterstock <\/p>\n

GSK PLC (LSE:GSK, NYSE:GSK)<\/a>\u00a0shares jumped to a three-month high after the drugmaker beat second-quarter expectations across its main measures and accelerated investment in its pipeline. <\/p>\n

Revenue rose 5% to \u00a38.41 billion, ahead of the \u00a38.25 billion City consensus. Adjusted earnings per share increased 9% to 50.5p, beating the 46.8p forecast by almost 8%. <\/p>\n

Vaccines sales grew 8% to \u00a32.28 billion, compared with expectations of \u00a32.1 billion. Shingrix revenue reached \u00a3888 million, topping the \u00a3867.8 million consensus, while sales of respiratory syncytial virus vaccine Arexvy more than doubled. <\/p>\n

Specialty Medicines also performed strongly, with sales up 14%. Respiratory, Immunology & Inflammation advanced 19%, Oncology rose 17% and HIV increased 10%. General Medicines declined 9%, however. <\/p>\n

GSK reaffirmed its full-year guidance, expecting sales growth in the upper half of its 3%-5% range and core operating profit growth in the upper half of its 7%-9% range. Core earnings growth is forecast in the lower half of the 7%-9% range. <\/p>\n

The company plans to more than double its phase III trial starts this year to over 20, accelerating seven late-stage assets across 18 indications. It also said it remains “on track” to generate more than \u00a340 billion of annual sales by 2031. <\/p>\n

A three-year restructuring programme was announced, targeting \u00a31.9 billion of annual savings by 2029, with most reinvested in research and development. <\/p>\n

Statutory operating profit fell 75% after a \u00a31.3 billion impairment linked mainly to cough drug camlipixant. GSK declared a 17p quarterly dividend. <\/p>\n

The shares surged\u00a06% to\u00a02,080p, their highest since mid-April. <\/p>\n

Analysts at Jefferies hailed a second quarter “of good quality”, with vaccines and specials more than offsetting softer general medicines. <\/p>\n

“Better product mix more than offsets higher opex leaving core operating income 5% ahead and core EPS 7% beat.” <\/p>\n

The cost-cutting plan was seen as “surprisingly strong”, about double what was expected. <\/p>\n

“The aim of the program is to protect the margin through the patent cliff but also to restructure the business and move R&D from Stevenage to Cambridge. With over double the number of Phase III trial initiations expected in 2026 to 20+, reinvestment will be part of it but this is a strong and unexpected move.” <\/p>\n

\u00a0 ** UPDATE: Adds broker comment ** <\/p>\n","protected":false},"excerpt":{"rendered":"GSK hits three-month high as vaccines help earnings top forecasts Proactive uses images sourced from Shutterstock GSK PLC…\n","protected":false},"author":2,"featured_media":98729,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[7920,20785,21214,22207,5250],"class_list":["post-98728","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-earnings-per-share","tag-gsk","tag-gsk-plc","tag-respiratory-syncytial-virus","tag-vaccines"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117049979189364222","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/98728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=98728"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/98728\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/98729"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=98728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=98728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=98728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}